SynCav1 Gene Therapy for CNS Disorders
12 Feb 2026
Theatre 1
Technology and Innovation
This session examines SynCav1 gene therapy as a potential approach for CNS disorders. Participants will gain insights into gene therapy design, delivery considerations, and translational strategies to expand therapeutic options for neurological diseases.
Key takeaways:
- Learn the principles behind SynCav1 gene therapy for CNS applications.
- Explore strategies for targeted delivery and effective expression in the CNS.
- Apply insights into translational development for neurological indications.
- Understand considerations for safety, efficacy, and clinical design.
- Gain perspectives on advancing gene therapies for complex CNS disorders.
